GFR90 was formed to commercialize and further develop a WEARABLE ARTIFICIAL KIDNEY. This remarkable device has been in development for almost five years and is entering clinical trials in the fall of 2020. There are over 800,000 dialysis patients in North America. Most of these must attend a dialysis clinic or hospital two to three times a week for dialysis because they suffer from end stage kidney disease, that is, their kidneys no longer work effectively. Although this is life-saving therapy, this intermittency creates medical, social, and mental health issues which result in a very low quality of life. Patients feel lethargic, nauseous, fatigue so much so that holding a full time job or attending school is very difficult. The solution is to change dialysis from an intermittent therapy to a continuous therapy. Just like healthy kidneys. This will smooth out the fluid and toxin accumulation and better balance the electrolytes - the three main function of kidneys. These intermittency issues with current dialysis are so severe that the FDA and White House have issued statements to try to address them by encouraging industry to solve the problem. GFR90 has the solution: a wearable dialysis machine that is lightweight and battery operated so patients wear it during normal activities every day - activities like preparing dinner, gardening, walking or even vacationing. This near continuous dialysis functions more like healthy kidneys and attenuates the huge swings in body fluids, toxins and electrolytes that create these problems. Scheduled to enter the market in North America within 3 years with their first wearable artificial kidney, GFR90 is further development and commercialization stages of this remarkable disruptive product. If you are interested in knowing more, please go to www.GFR90.com.